Drugs / Nab-paclitaxel
Nab-paclitaxel
Drug FDA approvedMarketed as Abraxane
Taxane mitotic inhibitor (albumin-bound paclitaxel)·First approved·2005·1 brand
- Registered trials
- 558
- Ongoing
- 185/ 33%
- Completed
- 215
- Indications
- 3
Approved indications by brand
| Brand | Indication |
|---|---|
| Abraxane | Metastatic breast cancer after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy |
| Locally advanced or metastatic non-small cell lung cancer in combination with carboplatin in patients not candidates for curative surgery/radiation | |
| Metastatic adenocarcinoma of the pancreas in combination with gemcitabine |
Clinical trial landscape
558 registered studies reference this molecule or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 2 | 238 | 89 | 84 | |
| Phase 1 | 111 | 28 | 55 | |
| Phase 1/2 | 102 | 21 | 39 | |
| Phase 3 | 78 | 38 | 27 | |
| Phase 2/3 | 10 | 6 | 1 | |
| Not applicable | 8 | 3 | 2 | |
| Early Phase 1 | 5 | 0 | 2 | |
| Unknown | 4 | 0 | 3 | |
| Phase 4 | 2 | 0 | 2 | |
| All phases | 558 | 185 | 215 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Mechanism of action
Paclitaxel component kills cancer cells by preventing normal microtubule breakdown during cell division.
Recent developments
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.